AtheroGenics Discontinues Highest Dose of AGI-1067

AtheroGenics will discontinue the 300-mg dose of AGI-1067, a diabetes treatment, in the ANDES trial.

The discontinuation resulted from a review of the adverse effects on the liver with the 300-mg dose seen in the Phase III ARISE trial. The ANDES trial will continue with the 75- and 150-mg doses, AtheroGenics said.

ANDES enrollment is expected to be completed before the end of the year.